VIDEOS AND WEBINARS

• Cell And Gene Therapies – U.S. Payer Trends

  Gain insights from U.S. payer interviews covering coverage processes, evidence requirements, and engagement strategies to accelerate market access from late-stage development through commercialization.

• The Transformative Potential Of AI In HEOR And Market Access

  HEOR teams are under pressure to move faster without sacrificing rigor. Discover how AI accelerates evidence synthesis, fills data gaps, and supports living models that meet HTA transparency standards.

• The Evolving Policy Landscape: U.S. And EU Pricing And Access

  U.S. and EU policy shifts are reshaping pricing, access, and launch strategy. Hear expert analysis on IRA, MFN, 340B, EU HTA Regulation, and the Biotech Act to stay ahead of 2025-2026 changes.

• Foundations And Implications For International Reference Pricing

  Reforms like the U.S. Most Favored Nation model are intensifying pressure on global launch strategies. Understand the tactics that protect value while expanding access.

• The Growing Role Of Real-World Evidence

  Regulators and HTA bodies are raising the bar on real-world evidence. Understand how JCAs, oncology registries, and EHR data are redefining what credible RWE looks like, and how to meet agency expectations.

• Integrated Quality, Regulatory, And Safety Services

  A single-vendor model for quality, regulatory, and safety services provides consistent project management and cost-effective scalability. Hear how integrated solutions support market entry and growth.